Canakinumab provides a significant reduction in disease severity, attack frequency, and acute phase reactant levels in FMF. Abs 1834 #ACR22 @RheumNow https://t.co/3JYDi7eaBU https://t.co/NepMkQniiB
Links:
Canakinumab Treatment in Familial Mediterranean Fever Patients with Colchicine …
http://ow.ly/bEfS50LA6zf
14-11-2022